Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Satellos Bioscience Inc. (NASDAQ:MSLE) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $19.75.

MSLE has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Satellos Bioscience in a report on Monday, August 17th. Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a report on Thursday, July 9th. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Canaccord Genuity Group raised Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Friday, August 7th.

Institutional Investors Weigh In On Satellos Bioscience

An institutional investor recently raised its stake in Satellos Bioscience stock. AWM Investment Company Inc. boosted its holdings in Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 305,000 shares of the company’s stock after buying an additional 90,000 shares during the period. AWM Investment Company Inc. owned approximately 1.46% of Satellos Bioscience worth $2,338,000 as of its most recent SEC filing.

Satellos Bioscience Stock Performance

Shares of MSLE stock opened at $9.05 on Thursday. Satellos Bioscience has a 52-week low of $5.30 and a 52-week high of $13.39. The stock has a market cap of $192.04 million, a price-to-earnings ratio of -4.71 and a beta of 1.53. The firm has a fifty day moving average of $9.17 and a 200-day moving average of $8.28.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.18). On average, sell-side analysts predict that Satellos Bioscience will post -2.08 earnings per share for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.